Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance
暂无分享,去创建一个
Mark Ellrichmann | J. Holst | M. Nauck | W. Schmidt | J. Meier | Jens J Holst | Michael A Nauck | M. Ellrichmann | Kirsten Vollmer | Birgit Baller | Wolfgang E Schmidt | Juris J Meier | K. Vollmer | B. Baller | Kirsten Vollmer | Birgit Baller
[1] J. Holst,et al. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas , 2007, Diabetologia.
[2] Sten Madsbad,et al. Reduced Incretin Effect in Type 2 Diabetes , 2007, Diabetes.
[3] J. Holst,et al. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects , 2007, Diabetologia.
[4] J. Holst,et al. Reduced Incretin Effect in Type 2 Diabetes - Cause or Consequence of the Diabetic State? Received for publication 23 January 2007 and accepted in revised form 3 May 2007. , 2007 .
[5] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[6] Sten Madsbad,et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. , 2006, European journal of endocrinology.
[7] Reawika Chaikomin,et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.
[8] J. Holst,et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. , 2006, Gastroenterology.
[9] M. Nauck,et al. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.
[10] J. Holst,et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans , 2006, Diabetologia.
[11] J. Holst,et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes , 2005, Diabetologia.
[12] M. Nauck,et al. Glucagon‐like peptide 1(GLP‐1) in biology and pathology , 2005, Diabetes/metabolism research and reviews.
[13] W. Creutzfeldt,et al. The incretin concept today , 1979, Diabetologia.
[14] M. Nauck,et al. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. , 2004, Diabetes.
[15] M. Nauck,et al. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide , 2004 .
[16] Jens J. Holst,et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes , 2004, Regulatory Peptides.
[17] J. Holst,et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. , 2004, American journal of physiology. Endocrinology and metabolism.
[18] J. Alvarado,et al. Endothelia of Schlemm's canal and trabecular meshwork: distinct molecular, functional, and anatomic features. , 2004, American journal of physiology. Cell physiology.
[19] J. Wishart,et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects , 1993, Diabetologia.
[20] J. Holst,et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.
[21] J. Wishart,et al. Gastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 1989, Diabetologia.
[22] W. Creutzfeldt,et al. New developments in the incretin concept , 1985, Diabetologia.
[23] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[24] T. M. Hayes,et al. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 2004, Diabetologia.
[25] J. Holst,et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.
[26] J. Holst,et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.
[27] J. Holst,et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. , 2003, Diabetes.
[28] L. Geddes. The first accurate measurement of systolic and diastolic blood pressure , 2002, IEEE Engineering in Medicine and Biology Magazine.
[29] M. Nauck,et al. Gastric Inhibitory Polypeptide: the neglected incretin revisited , 2002, Regulatory Peptides.
[30] M. Horowitz,et al. Gastric emptying in diabetes: clinical significance and treatment , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[31] J. Holst,et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.
[32] J. Holst,et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.
[33] J. Holst,et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.
[34] J. Holst,et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.
[35] J. Holst,et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. , 2000, The Journal of clinical endocrinology and metabolism.
[36] J. Holst,et al. Structure, measurement, and secretion of human glucagon-like peptide-2 , 2000, Peptides.
[37] Rolf Mentlein,et al. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.
[38] J. Holst,et al. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations , 1999, Diabetologia.
[39] J. Holst,et al. The pathogenesis of NIDDM involves a defective expression of the GIP receptor , 1997, Diabetologia.
[40] T. Usdin,et al. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. , 1996, The American journal of physiology.
[41] M. Nauck,et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.
[42] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[43] J. Holst,et al. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. , 1991, The Journal of clinical investigation.
[44] T. Jenssen,et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. , 1990, Diabetes.
[45] J. Holst,et al. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.
[46] T. Krarup. Immunoreactive gastric inhibitory polypeptide. , 1988, Endocrine reviews.
[47] R. Rizza,et al. Incretin Effect Due to Increased Secretion and Decreased Clearance of Insulin in Normal Humans , 1988, Diabetes.
[48] S. Madsbad,et al. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. , 1987, Metabolism: clinical and experimental.
[49] J. Holst,et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.
[50] R. Eaton,et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.
[51] J. Holst. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33–69) of glicentin , 1983, Regulatory Peptides.
[52] J. Holst. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. , 1982, The Biochemical journal.
[53] J. Halter,et al. Insulin secretion in diabetes mellitus. , 1981, The American journal of medicine.
[54] J. Brown,et al. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. , 1978, Endocrinology.
[55] J. Brown,et al. Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus , 1977, Diabetes.
[56] W. A. Müller,et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.